Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | TUBB | P07437 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19358930 | 0.92 | CA12 (0.62) | MAPK1TUBBMAPTCA12CA9 | |
| SCHEMBL19358867 | 0.84 | CXCR4 (0.69) | CXCR4TUBBHTTMAPTKEAP1 | |
| SCHEMBL19358874 | 0.84 | TUBB (0.64) | CXCR4TUBBHTTMAPTKEAP1 | |
| SCHEMBL19358848 | 0.84 | HPGD (0.71) | CXCR4MAPK1TUBBHTTMAPT | |
| SCHEMBL1032002 | 0.83 | MAPK1 (0.77) | MAPK1HTTHPGDCYP3A4L3MBTL1 | |
| SCHEMBL19358860 | 0.82 | CXCR4 (0.82) | CXCR4HTTMAPTKEAP1CA12 | |
| SCHEMBL19358887 | 0.82 | MAPT (0.82) | CXCR4HTTMAPTCA12CA9 | |
| SCHEMBL19358890 | 0.80 | POLB (0.63) | CXCR4TUBBMAPTCA12CA9 | |
| SCHEMBL19358866 | 0.80 | MEN1 (0.60) | TUBBMAPTCA12CA9HPGD | |
| SCHEMBL1034235 | 0.80 | HPGD (0.72) | MAPK1HPGDAPEX1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429588-B1 | AMIDE-SULFAMIDE DERIVATIVES, COMPOSITIONS, AND USES RELATED TO CXCR4 INHIBITION | UNIV EMORY (US) | 2024-09-18 | — | — | EP | disclosed |
| US-10669270-B2 | Amide-sulfamide derivatives, compositions, and uses related to CXCR4 inhibition | EMORY UNIVERSITY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190084980-A1 | Amide-Sulfamide Derivatives, Compositions, and Uses Related to CXCR4 Inhibition | EMORY UNIVERSITY (US) | 2019-03-21 | — | — | US | disclosed |
| EP-3429588-A1 | AMIDE-SULFAMIDE DERIVATIVES, COMPOSITIONS, AND USES RELATED TO CXCR4 INHIBITION | Emory University (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017160832-A1 | AMIDE-SULFAMIDE DERIVATIVES, COMPOSITIONS, AND USES RELATED TO CXCR4 INHIBITION | EMORY UNIVERSITY (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084980-A1 | Amide-Sulfamide Derivatives, Compositions, and Uses Related to CXCR4 Inhibition | CXCR4, CXCL12, CXCR2 | CXCR4 1/4885MAPK1 1560/4885TUBB 4478/4885 |
| US-10669270-B2 | Amide-sulfamide derivatives, compositions, and uses related to CXCR4 inhibition | CXCR4, CXCL12, CXCR2 | CXCR4 1/4885MAPK1 1560/4885TUBB 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.